JP2017528473A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528473A5
JP2017528473A5 JP2017513751A JP2017513751A JP2017528473A5 JP 2017528473 A5 JP2017528473 A5 JP 2017528473A5 JP 2017513751 A JP2017513751 A JP 2017513751A JP 2017513751 A JP2017513751 A JP 2017513751A JP 2017528473 A5 JP2017528473 A5 JP 2017528473A5
Authority
JP
Japan
Prior art keywords
composition
composition according
treatment
fluoro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017513751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528473A (ja
JP6647287B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/071391 external-priority patent/WO2016042112A1/en
Publication of JP2017528473A publication Critical patent/JP2017528473A/ja
Publication of JP2017528473A5 publication Critical patent/JP2017528473A5/ja
Application granted granted Critical
Publication of JP6647287B2 publication Critical patent/JP6647287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017513751A 2014-09-23 2015-09-18 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド Active JP6647287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185892.8 2014-09-23
EP14185892 2014-09-23
PCT/EP2015/071391 WO2016042112A1 (en) 2014-09-23 2015-09-18 Quinoline carboxamides for use in the treatment of multiple myeloma

Publications (3)

Publication Number Publication Date
JP2017528473A JP2017528473A (ja) 2017-09-28
JP2017528473A5 true JP2017528473A5 (en:Method) 2018-10-11
JP6647287B2 JP6647287B2 (ja) 2020-02-14

Family

ID=51660309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513751A Active JP6647287B2 (ja) 2014-09-23 2015-09-18 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド

Country Status (15)

Country Link
US (2) US9956212B2 (en:Method)
EP (1) EP3041472B1 (en:Method)
JP (1) JP6647287B2 (en:Method)
KR (1) KR102533033B1 (en:Method)
CN (1) CN107108510B (en:Method)
AU (1) AU2015316824B2 (en:Method)
CA (1) CA2961978C (en:Method)
EA (1) EA030948B1 (en:Method)
ES (1) ES2631194T3 (en:Method)
IL (1) IL251043B (en:Method)
MX (1) MX366837B (en:Method)
NZ (1) NZ730816A (en:Method)
PL (1) PL3041472T3 (en:Method)
WO (1) WO2016042112A1 (en:Method)
ZA (1) ZA201702377B (en:Method)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108510B (zh) * 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺
KR20220149579A (ko) * 2020-03-03 2022-11-08 액티브 바이오테크 에이비 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
PL4185292T3 (pl) 2020-07-23 2025-10-13 Erasmus University Medical Center Rotterdam Białka s100 jako nowe cele terapeutyczne w przypadku nowotworów mieloproliferacyjnych
MX2023008016A (es) 2021-01-18 2023-07-13 Active Biotech Ab Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
JP2024524158A (ja) 2021-07-02 2024-07-05 アクティブ バイオテック エイビー タスキニモドを含有する医薬製品および前記製品の純度を評価する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US9469876B2 (en) * 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
EA021171B1 (ru) 2010-07-09 2015-04-30 Эктив Байотек Аб Способ получения хинолин-3-карбоксамидов
US20140148350A1 (en) * 2010-08-18 2014-05-29 David Spetzler Circulating biomarkers for disease
WO2012034543A1 (es) 2010-09-13 2012-03-22 Universidad De Costa Rica Conector estructural para bambú
FR2967353B1 (fr) * 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN107108510B (zh) * 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺

Similar Documents

Publication Publication Date Title
JP2017528473A5 (en:Method)
JP2010265321A5 (en:Method)
JP2016040288A5 (en:Method)
JP2012255026A5 (en:Method)
JP2015505296A5 (en:Method)
JP2013509429A5 (en:Method)
JP2010502730A5 (en:Method)
JP2009531376A5 (en:Method)
JP2016529245A5 (en:Method)
JP2013542247A5 (en:Method)
JP2017505285A5 (en:Method)
JP2012533546A5 (en:Method)
JP2016525121A5 (en:Method)
JP2019526596A5 (en:Method)
JP2011201907A5 (en:Method)
JP2013508279A5 (en:Method)
JP2016515582A5 (en:Method)
JP2013542261A5 (en:Method)
JP2015511609A5 (en:Method)
JP2017520613A5 (en:Method)
JP2017517538A5 (en:Method)
JP2014528464A5 (en:Method)
JP2014505107A5 (en:Method)
JP2016510326A5 (en:Method)
JP2017508817A5 (en:Method)